Related references
Note: Only part of the references are listed.miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1
Wei-Wei Wang et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells
Emiko Akashi et al.
ONCOLOGY REPORTS (2017)
A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma
Yuanwei Huang et al.
INTERNATIONAL JOURNAL OF SURGERY (2017)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Nanotechnology inspired tools for mitochondrial dysfunction related diseases
Ru Wen et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Galectin-9: An anticancer molecule for gallbladder carcinoma
Tomoko Tadokoro et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Chemoradiotherapy for esophageal squamous cell cancer
Yusuke Sasaki et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Galectin expression in cancer diagnosis and prognosis: A systematic review
Victor L. Thijssen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
Upregulation of miR-582-5p inhibits cell proliferation, cell cycle progression and invasion by targeting Rab27a in human colorectal carcinoma
X. Zhang et al.
CANCER GENE THERAPY (2015)
Galectin-9 as an important marker in the differential diagnosis between oral squamous cell carcinoma, oral leukoplakia and oral lichen planus
Janusa Maria Muniz et al.
IMMUNOBIOLOGY (2015)
Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo
Koji Fujita et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences
Kai Wang et al.
ONCOLOGIST (2015)
Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest
Kiyoyuki Kobayashi et al.
ONCOLOGY REPORTS (2015)
miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3
Yi Zhang et al.
TUMOR BIOLOGY (2015)
miRNA in hepatocellular carcinoma
Asahiro Morishita et al.
HEPATOLOGY RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Changed Expression of E-cadherin and Galectin-9 in Oral Squamous Cell Carcinomas but Lack of Potential as Prognostic Markers
Siew Wui Chan et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies
Shravan Madireddi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Regulation of osteoclastogenesis through Tim-3:possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction
Kanako Moriyama et al.
LABORATORY INVESTIGATION (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Galectin fingerprinting in naso-sinusal diseases
Anaelle Duray et al.
ONCOLOGY REPORTS (2014)
Correction: A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection
John A. Mengshol et al.
PLoS One (2014)
Therapeutic Effects of MicroRNA-582-5p and -3p on the Inhibition of Bladder Cancer Progression
Keita Uchino et al.
MOLECULAR THERAPY (2013)
The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells
Valerie R. Wiersma et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia
Junya Kuroda et al.
MOLECULAR CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways
T. Kobayashi et al.
LEUKEMIA (2010)
Galectin-9 Is a High Affinity IgE-binding Lectin with Anti-allergic Effect by Blocking IgE-Antigen Complex Formation
Toshiro Niki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation
Yongjie Wei et al.
AUTOPHAGY (2008)
Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis
Masako Seki et al.
CLINICAL IMMUNOLOGY (2008)
Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma
Meiyan Liang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions
Keiko Nagahara et al.
JOURNAL OF IMMUNOLOGY (2008)
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age
Linda Morris Brown et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
JNK signaling in apoptosis
D. N. Dhanasekaran et al.
ONCOGENE (2008)
Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family
Nobumitsu Miyanishi et al.
GLYCOBIOLOGY (2007)
p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65
Beibei Cai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
Farin Kamangar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Ribo-gnome: The big world of small RNAs
PD Zamore et al.
SCIENCE (2005)
Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins
N Nishi et al.
FEBS LETTERS (2005)
Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway
Y Kashio et al.
JOURNAL OF IMMUNOLOGY (2003)
The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity
G van Loo et al.
CELL DEATH AND DIFFERENTIATION (2002)
Galectin-9 in physiological and pathological conditions
M Hirashima et al.
GLYCOCONJUGATE JOURNAL (2002)
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
CY Du et al.
CELL (2000)
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
AM Verhagen et al.
CELL (2000)
Share Paper
